

Real-world experience with reversal of dabigatran by id

Thrombosis Research

197, 179-184

DOI: [10.1016/j.thromres.2020.11.010](https://doi.org/10.1016/j.thromres.2020.11.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dabigatran etexilate/idarucizumab. Reactions Weekly, 2021, 1844, 145-145.	0.0	0
2	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2021, 77, 2987-3001.	2.8	69
3	Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 22.	1.0	0
4	Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12535.	2.3	2
5	Anticoagulants and Antiplatelet Drugs. , 2021, , .		0
7	Effectiveness and Safety of Idarucizumab for Periprocedural Cardiac Tamponade After Catheter Ablation of Atrial Fibrillation in Dabigatran Recipients: A Retrospective Controlled Study. American Journal of Cardiovascular Drugs, 0, , .	2.2	0
8	Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke. Journal of Thrombosis and Thrombolysis, 2023, 55, 506-518.	2.1	1
9	Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials. Medicina (Lithuania), 2023, 59, 881.	2.0	3
10	Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes. Thrombosis Research, 2023, 228, 21-32.	1.7	2
11	Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100201.	2.3	1